Protein kinase inhibitors for the treatment of prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Protein kinase inhibitors for the treatment of prostate cancer

Published:2021-05-14 Issue:14 Volume:22 Page:1889-1899
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Chau Vincent¹,Madan Ravi A.¹,Aragon-Ching Jeanny B.²³^ORCID

Affiliation:

1. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

2. Genitourinary Cancers, Inova Medical Group, Inova Schar Cancer Institute, Fairfax, VA, USA

3. Department of Internal Medicine, University of Virginia University School of Medicine, Charlottesville, VA, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2021.1925250

Reference77 articles.

1. Cancer statistics, 2020

2. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

3. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer

4. Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells

5. Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance of prostate cancer to kinase inhibitors;Therapy Resistance in Prostate Cancer;2024

2. The Rate of Phosphatase and Tensin (PTEN) Gene Expression Loss in Prostate Cancer and its Link to Tumor Upgrading;UROL J;2023

3. Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?;Critical Reviews in Clinical Laboratory Sciences;2023-10-26

4. Recent advances and future perspectives in the therapeutics of prostate cancer;Experimental Hematology & Oncology;2023-09-22

5. The Oncogenic Protein Kinase/ATPase RIOK1 Is Up-Regulated via the c-myc/E2F Transcription Factor Axis in Prostate Cancer;The American Journal of Pathology;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3